Sign up
Pharma Capital

AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
1520839966_lungs.jpg
The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer

AstraZeneca PLC (LON:AZN) said the timeline for its closely-followed MYSTIC clinical trial, treating patients with late-stage lung cancer has been pushed back.

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first.

MYSTIC deployed Imfinzi, developed by AZ’s US biotechnology arm MedImmune, in combination with tremelimumab, an antibody treatment also created by the company’s American research arm.

The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer.

The trial is being conducted in 167 centres across 17 countries, including the US, Canada, Europe, and parts of Asia.

Ian_55ae0ddd437b7.jpg


Register here to be notified of future AZN Company articles
View full AZN profile View Profile
Article

AstraZeneca in cancer drug setback

View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.